BMS’ Camzyos and Handok’s Empaveli pass the DREC review
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.07.09 05:49:56
가나다라
0
Mitsubishi Tanabe Pharma’s 'Uplizna Inj' received conditional approval for reimbursement appropriateness
Bristol Myers Squibb Korea’s 'Camzyos Cap,' a treatment for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), has passed the Drug Reimbursement Evaluation Committee (DREC) review after reconsideration.
Handok’s 'Empaveli Inj,' a treatment for paroxysmal nocturnal hemoglobinuria (PNH), also obtained approval for reimbursement and moved on to negotiations.
The Health Insurance Review and Assessment Service (HIRA) commenced the 7th Drug Reimbursement Evaluation Committee (DREC) of 2024 and announced that it had decided the appropriateness of reimbursement for these drugs.
▲The review outcome of assessing the appropriateness of benefit coverage for drugs that have applied for a decision:
Three pharmaceuticals have been considered for this round of DREC review. The symptoma
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)